The Race for Hydroxamate-Based Zirconium-89 Chelators.

Feiner, Irene V J; Brandt, Marie; Cowell, Joseph; Demuth, Tori; Vugts, Daniëlle; Gasser, Gilles; Mindt, Thomas L

Feiner, Irene V J; Brandt, Marie; Cowell, Joseph; Demuth, Tori; Vugts, Daniëlle; Gasser, Gilles; Mindt, Thomas L.

Afiliación

Feiner IVJ; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, 1090 Vienna, Austria.
Brandt M; Division of Nuclear Medicine, Department of Biomedical Imaging and Imaging Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
Cowell J; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, 1090 Vienna, Austria.
Demuth T; Division of Nuclear Medicine, Department of Biomedical Imaging and Imaging Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
Vugts D; Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, Chimie ParisTech, PSL University, CNRS, 75005 Paris, France.
Gasser G; TU Wien, Institut für Angewandte Synthesechemie, Getreidemarkt 9, 1060 Wien, Austria.
Mindt TL; TU Wien, Center for Labeling and Isotope Production, Stadionallee 2, 1020 Wien, Austria.

Cancers (Basel) ; 13(17)2021 Sep 04.

Article en En | MEDLINE | ID: mdl-34503276

Palabras clave

DFO; desferrioxamine; hydroxamate chelators; immunoPET; zirconium-89

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Determinantes_sociais_saude Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google